What's Happening?
Akeso, in partnership with Summit Therapeutics, has reported promising results from a Phase 3 trial of their VEGF/PD-1 therapy, ivonescimab, for advanced squamous non-small cell lung cancer (NSCLC). The trial, conducted in China, demonstrated a four-month
improvement in overall survival compared to the standard of care. The therapy showed a statistically significant hazard ratio of 0.66, indicating a substantial reduction in the risk of death. These findings were presented at the American Society for Clinical Oncology meeting, highlighting the potential of this therapy to change clinical practice.
Why It's Important?
The success of ivonescimab could have significant implications for the treatment of lung cancer, particularly in providing an alternative to existing therapies like Keytruda. If approved, this therapy could offer a new option for patients with advanced squamous NSCLC, potentially improving survival rates. The results also relieve pressure on Summit Therapeutics, which is seeking to establish itself in the competitive oncology market. The therapy's success in China sets a precedent for its potential approval and use in other regions, including the United States.
What's Next?
Summit Therapeutics has submitted ivonescimab to the FDA for approval as part of a combination chemotherapy regimen for certain lung cancer patients. A decision is expected in November. The company will also need to replicate these results in a non-Chinese dataset to support global approval. The upcoming data from the HARMONi-3 trial will be crucial in determining the therapy's broader applicability and potential market impact. Success in these trials could position Summit and Akeso as significant players in the oncology field.
